Discovery and Development of Monoclonal Antibodies Targeting Tumor Neo-Epitopes
Philip Arlen,
President and CEO,
Precision Biologics, Inc
An allogeneic cancer vaccine developed from human tumors surgically resected had demonstrated anti-tumor responses in a clinical trial. These responses correlated with the ability of patients to mount and sustain antibody responses against the vaccine. This vaccine was utilized as a platform to identify monoclonal antibodies with tumor sensitivity, specificity and anti-tumor killing.
|
|
